BEBT-908 plus rituximab for relapsed large B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new drug, BEBT-908, combined with rituximab for people with diffuse large B-cell lymphoma that has come back or not responded to at least one prior treatment that included a CD20 antibody. The goal is to see if this new combination works better than standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have diffuse large B-cell lymphoma that returned or did not respond after at least one prior treatment that included a CD20 antibody (like rituximab).
- You have at least one measurable tumor that can be seen on a CT or MRI scan.
- Your overall health is good enough for daily activities (ECOG score of 0-2).
- Your blood counts and liver/kidney function are within acceptable ranges.
- You are not pregnant or breastfeeding and agree to use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called SCTB35 combined with two common chemotherapy drugs (gemcitabine and oxaliplatin) for patients with diffuse large B-cell lymphoma that has come back or stopped responding to previous treatment. The goal is to see if this combination is safe and helps shrink the cancer.
This trial tests a drug called linperlisib combined with standard chemotherapy and immunotherapy for people with large B-cell lymphoma that has come back or not responded to one prior treatment.
This study tests a new drug (BEBT-908) combined with standard chemotherapy for people with untreated peripheral T-cell lymphoma. The goal is to see if the combination helps shrink tumors.
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
This trial tests a combination of two immunotherapy drugs (rimegepant and glofitamab) plus a special cell therapy called CD19 CAR-T for people with large B-cell lymphoma that has not responded to or has returned after previous treatment. The goal is to see if this combination can better control the lymphoma and improve outcomes.
This trial tests a new combination of drugs for people with a type of lymphoma (diffuse large B-cell lymphoma) that has come back or not responded to treatment. The goal is to see if this combination can help control the cancer.
Hear when a new Relapsed/Refractory Diffuse Large B-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.